company background image
INM logo

InMed Pharmaceuticals NasdaqCM:INM Stock Report

Last Price

US$5.50

Market Cap

US$3.9m

7D

28.2%

1Y

-31.3%

Updated

06 Dec, 2024

Data

Company Financials

InMed Pharmaceuticals Inc.

NasdaqCM:INM Stock Report

Market Cap: US$3.9m

INM Stock Overview

A clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. More details

INM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

InMed Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for InMed Pharmaceuticals
Historical stock prices
Current Share PriceUS$5.50
52 Week HighUS$15.70
52 Week LowUS$2.41
Beta0.65
11 Month Change21.68%
3 Month Change3.11%
1 Year Change-31.25%
33 Year Change-99.27%
5 Year Change-99.82%
Change since IPO-99.87%

Recent News & Updates

Recent updates

InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M

Sep 26

InMed Pharma announces $6M private placement

Sep 09

InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens

Jul 25

InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement

Jul 13

InMed To Acquire Rare Cannabinoid Manufacturer BayMedica

Jul 02

Shareholder Returns

INMUS PharmaceuticalsUS Market
7D28.2%0.8%1.0%
1Y-31.3%13.4%32.3%

Return vs Industry: INM underperformed the US Pharmaceuticals industry which returned 14% over the past year.

Return vs Market: INM underperformed the US Market which returned 32.4% over the past year.

Price Volatility

Is INM's price volatile compared to industry and market?
INM volatility
INM Average Weekly Movement15.6%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement6.3%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stable Share Price: INM's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: INM's weekly volatility has decreased from 31% to 16% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
198113Eric Adamswww.inmedpharma.com

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products.

InMed Pharmaceuticals Inc. Fundamentals Summary

How do InMed Pharmaceuticals's earnings and revenue compare to its market cap?
INM fundamental statistics
Market capUS$3.89m
Earnings (TTM)-US$6.82m
Revenue (TTM)US$4.96m

0.8x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INM income statement (TTM)
RevenueUS$4.96m
Cost of RevenueUS$3.39m
Gross ProfitUS$1.57m
Other ExpensesUS$8.39m
Earnings-US$6.82m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-9.49
Gross Margin31.71%
Net Profit Margin-137.42%
Debt/Equity Ratio0%

How did INM perform over the long term?

See historical performance and comparison